WHALE.TIPS VIEWER

Financial News: Novavax approved for emergency use

Financial News:

Novavax approved for emergency use

Vaccine shot

With an emergency approval for use by the WHO, Novavax is ripping in premarket, and options have been historically adjusting very well for this stock.

The stock increased after World Health Organization granted the vaccine company and the Serum Institute of India an emergency use authorization for their Covid-19 vaccine.

Covovax, which is manufactured and marketed by the Serum Institute for India and other developing nations, has been awarded emergency use status by the WHO.

Novavax's Covid-19 vaccine is protein-based, unlike the vaccines developed by the Pfizer (PFE) and BioNTech (BNTX) alliance and Moderna (MRNA), which are based on messenger RNA drug technology.

NOTE: This is not an endorsement or rejection of vaccines. This is a stock market news item.

Photo: A vaccine is a biological preparation that provides active acquired immunity to a particular infectious disease.

NVAX

Novavax Inc
Wed, Jun 29, 22 6:00 PM UTC
Price: $51.71
Volume 91499
Tue, Jun 28, 22 (EOD)
Price: $51.06
Volume 4849580

Related:

    NVAX

    Novavax Inc
    Wed, Jun 29, 22 6:00 PM UTC
    Price: $51.71
    Volume 91499
    Tue, Jun 28, 22 (EOD)
    Price: $51.06
    Volume 4849580

    Content ID: 1640004014 Created Monday, December 20, 2021 12:40 PM UTC by Aaron Stipkovich, Updated Monday, December 20, 2021 12:56 PM UTC by Aaron Stipkovich.